JERUSALEM--(BUSINESS WIRE)--Dec. 22, 2011-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that Dr. Rob Koremans, has been appointed President and CEO, Teva Europe and will join the company in March 2012. Dr. Koremans joins Teva after serving as CEO for Zentiva and most recently Senior Vice President Generic Strategy and Development at Sanofi-Aventis.
After six intensive years, Dr. Gerard van Odijk, Teva Europe’s current President and CEO has decided to step down.
In the next few months, Dr. Koremans and Dr. van Odijk will work closely together to ensure a smooth transition. Dr. van Odijk will remain with Teva to support the EU region for the remainder of 2012.
Shlomo Yanai, President and CEO of Teva Pharmaceutical Industries, said, “I would like to express my personal and profound thanks to Gerard van Odijk for his leadership of Teva in Europe. Under his management, our business in Europe has been transformed as Teva became the undisputed generics leader in this major and growing market and established a strong position in specialty pharmaceuticals. I respect Gerard's decision to step down and spend more time with his family, and I wish him a lot of success in the future. I am very confident that Rob Koremans, together with our strong European management, will continue our success story across Europe”.
Dr. Rob Koremans (49) holds a medical degree from Erasmus University of Rotterdam, Netherlands. He began his career in 1988 at Sanofi SA. In 1993 he joined the Serono Group and was appointed Vice-President, Europe in 1998; from 2007 to 2009, Rob was Chief Executive Officer of Cryo-Save, Europe’s leading Stem Cell Storage Company. He returned to Sanofi in 2009 as Senior Vice President, Generics Europe, Sanofi-Aventis, and CEO of Zentiva. He was appointed President of Zentiva in July 2010 and later became Sanofi’s Senior Vice President Generic Strategy and Development.
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 47,000 people around the world and reached $16.1 billion in net sales in 2010.
Teva’s Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which we may obtain U.S. market exclusivity for certain of our new generic products and regulatory changes that may prevent us from utilizing exclusivity periods, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic version of Protonix®, the extent to which any manufacturing or quality control problems damage our reputation for high quality production, the effects of competition on sales of our innovative products, especially Copaxone® (including potential generic and oral competition for Copaxone®), the impact of continuing consolidation of our distributors and customers, our ability to identify, consummate and successfully integrate acquisitions (including the acquisition of Cephalon), interruptions in our supply chain or problems with our information technology systems that adversely affect our complex manufacturing processes, intense competition in our specialty pharmaceutical businesses, any failures to comply with the complex Medicare and Medicaid reporting and payment obligations, our exposure to currency fluctuations and restrictions as well as credit risks, the effects of reforms in healthcare regulation, adverse effects of political or economical instability, major hostilities or acts of terrorism on our significant worldwide operations, increased government scrutiny in both the U.S. and Europe of our agreements with brand companies, dependence on the effectiveness of our patents and other protections for innovative products, our ability to achieve expected results through our innovative R&D efforts, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, uncertainties surrounding the legislative and regulatory pathway for the registration and approval of biotechnology-based products, potentially significant impairments of intangible assets and goodwill, potential increases in tax liabilities resulting from challenges to our intercompany arrangements, our potential exposure to product liability claims to the extent not covered by insurance, the termination or expiration of governmental programs or tax benefits, current economic conditions, any failure to retain key personnel or to attract additional executive and managerial talent, environmental risks and other factors that are discussed in our Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission.
Source: Teva Pharmaceutical Industries Ltd.